The genomic IP portfolio assigned to Ryogen includes 17 patents and patent applications.

Contrary to the fading concept of "junk" DNA, the AmP patent and the pending patent applications place special focus on non-coding sequences unique to each target gene. In addition to providing a greatly expanded scope for detection of functionally significant mutations, these unique non-coding sequences will likely be found to play a key role in development of optimized gene therapy and preparations of superior transgenic animal models and recombinant proteins.